Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 43 clinical trials
featured
A 52-week, phase 3, multicentre, randomised, double blind, efficacy and safety study comparing GSK3196165 with placebo and with tofacitinib, in combination with MTX in participants with moderately to severely active RA who have an inadequate response to MTX.

A 52-week, phase 3, multicentre, randomised, double blind, efficacy and safety study comparing GSK3196165 with placebo and with tofacitinib, in combination with MTX in

tofacitinib
  • 55 views
  • 23 Nov, 2020
  • 1 location
featured
A3921210 OVATION  

This study, A3921210 is designed to evaluate the efficacy, safety and pharmacokinetics (PK) of tofacitinib in pediatric participants with moderately to severely active UC. In the

sulfasalazine
cancer
pediatric ulcerative colitis
corticosteroids
azathioprine
  • 0 views
  • 14 Jun, 2021
  • 1 location
featured
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Study Of The Efficacy And Safety Of tofacitinib In Subjects With Active Ankylosing Spondylitis (AS).

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Study Of The Efficacy And Safety Of tofacitinib In Subjects With Active Ankylosing Spondylitis (AS).  

  • 171 views
  • 23 Nov, 2020
  • 1 location
featured
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of ABT-494 for Induction and Maintenance Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of ABT-494 for Induction and Maintenance Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis

  • 248 views
  • 25 Mar, 2021
  • 1 location
A Safety Efficacy And Pharmacokinetics Study Of Tofacitinib In Pediatric Patients With sJIA

A randomized withdrawal study in which responders to open-label treatment with tofacitinib will be randomized in a 1:1 ratio to tofacitinib or placebo in a double-blind phase. In the double

  • 134 views
  • 24 May, 2021
  • 93 locations
Tofacitinib Citrate Topical Gel 3.2% FDA BA Bridging Study

This is a Phase 1, single center, open-label, fixed sequence, two-period pharmacokinetic (PK) study to evaluate the safety and relative systemic bioavailability of topical and oral tofacitinib

  • 0 views
  • 19 Mar, 2021
  • 1 location
Long-Term Safety Study Of Tofacitinib In Patients With Juvenile Idiopathic Arthritis

Evaluate long-term safety and tolerability of tofacitinib in patients with JIA, who have previously participated in tofacitinib JIA studies.

treatment regimen
arthritis
DMARD
  • 294 views
  • 01 Jun, 2021
  • 172 locations
Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate

weekly, tofacitinib capsules (cap) 5 mg twice a day or placebo (three arms, each placebo arm will have 12 weeks placebo followed by 40 weeks active treatment) respectively, all in combination with MTX

arthralgia
erosion
methotrexate
tofacitinib
  • 488 views
  • 14 May, 2021
  • 207 locations
TO ASSESS THE EFFICACY AND SAFETY OF PF-06650833 PF-06651600 AND TOFACITINIB ALONE AND IN COMBINATION IN PARTICIPANTS WITH ACTIVE RHEUMATOID ARTHRITIS WITH AN INADEQUATE RESPONSE TO METHOTREXATE

Dual objectives of increased efficacy compared to currently available SoC RA drugs and maintaining a favourable benefit - risk relationship.

erythrocyte sedimentation
high sensitivity
tofacitinib
methotrexate
rheumatism
  • 17 views
  • 09 Jun, 2021
  • 181 locations
Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic (cs)/Biologic (b) Disease Modifying Anti-rheumatic Drugs (DMARDs)

SC weekly, tofacitinib capsules (cap) 5 mg twice a day or placebo (three arms, each placebo arm will have 12 weeks placebo followed by 40 weeks active treatment) respectively, all in combination with

sulfasalazine
chloroquine
leflunomide
rheumatic diseases
methotrexate
  • 284 views
  • 14 May, 2021
  • 224 locations